PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03013491 |
Recruitment Status :
Completed
First Posted : January 6, 2017
Last Update Posted : February 9, 2022
|
Sponsor:
CytomX Therapeutics
Information provided by (Responsible Party):
CytomX Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | October 6, 2021 |
Actual Study Completion Date : | October 6, 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):